MultiVu Video Feed: FDA Approves DORIBAX(TM) (doripenem for injection) for the Treatment of Complicated Intra-abdominal and Complicated Urinary Tract ...( The U.S. Food and Drug Administra...),Health

The U.S. Food and Drug Administration (FDA) has approved DORIBAX(TM) (doripenem for injection) as a new treatment for complicated intra-abdominal and complicated urinary tract infections, including pyelonephritis. DORIBAX has demonstrated activity against a wide range of Gram-positive and Gram-negative bacteria - including Pseudomonas -- that cause these serious infections.

According to the CDC, in the U.S., nearly 2 million people acquire bacterial infections in hospitals each year, 90,000 will die as a result. 70% of those infections are caused by pathogens resistant to at least one drug. In 1998, the total annual cost of antimicrobial resistance to U.S. society was at least $5 billion USD. Gram-negative infections quickly are becoming a top concern of doctors in the hospital setting.

For more information visit: http://www.cdc.gov and http://www.who.int

SATELLITE FEEDS:

Monday, October 15th, 2007 Tuesday, October 16th, 2007

1:30 PM - 1:45 PM ET 1:00 PM - 1:15 PM ET

Galaxy 25 Galaxy 26

C-Band C-Band

Transponder 13 Transponder 24

Downlink Freq. 3960 Vertical Downlink Freq. 4180 Horizontal

Preview and access this video on Pathfire DMG: Slug # 28864

Search within the PR Newswire or MultiVu section by story ID # 28864 or by headline

For technical assistance call Pathfire Customer Care at 1-888-345-0489 or e-mail support@pathfire.com

NEWS: New Anti-infective, DORIBAX, effective against a wide range of resistant gram-positive and gram-negative pathogens.

FORMAT: B-roll and Soundbites

ADDITIONAL RESOURCES: Video, contact information and more available at: http://ww
'/>"/>